ADAMA: Margins Recovered Before Prices, and Now 2026 Has to Prove It Holds

Getting to Know the Company

ADAMA enters the 2025 annual report from a meaningfully better place than where it stood a year earlier. It is still a global crop protection company operating in a market with active ingredient overcapacity, weak crop prices and cautious last-minute customer ordering. Yet inside that environment it lifted adjusted EBITDA by 25% to $486 million, expanded the margin to 13.3%, and increased free cash flow to $231 million. What is working right now is internal operating discipline, not a friendly industry cycle.

This is primarily an off-patent crop protection business, with differentiation created through formulations, registrations and commercial reach. Roughly 97% of sales come from outside Israel, the company has direct presence in all top 20 markets, and it employed 5,070 people at year-end. On $3.66 billion of sales, that works out to about $722 thousand of revenue per employee. This is not a story driven by one molecule or one launch. The economics are shaped by raw material costs, product availability, distributor credit terms, manufacturing efficiency and local commercial execution.

There is another layer that matters early for an Israeli reader. ADAMA is listed in Tel Aviv as a bond issuer only, and it is wholly owned by ADAMA Ltd. That means the local read is not about equity rerating. It is about credit quality, financing flexibility, and whether operating improvement is reaching the debt layer rather than only the management deck.

A superficial reader may see positive adjusted net income and a 1.9x Net Debt/EBITDA ratio and conclude that the turnaround is already complete. That is the wrong read. The 1.9x ratio is based on covenant net debt that excludes securitization debt and SG loans, while the board report shows total net debt of $1.639 billion. The cash-flow improvement also did not come with a lighter inventory position or a genuine return of pricing power. It came in a year when sales still declined, inventory still rose, and the company leaned on better collections, longer payable terms and an aggressive bond buyback. That is why 2026 looks like a proof year, not a comfort year.

Events and Triggers

The central insight is that ADAMA's story changed from the inside before it changed outside. The end market still offers weak pricing, but management improved the cost base, simplified the organization and reworked the financing layer. That does not remove the industry problem, but it explains why 2025 looks much better than 2024 even without a clean demand recovery.

Fight Forward moved from language to numbers

The Fight Forward program, launched in early 2024, is now visible in the report rather than only in management messaging. Better country and product focus, organizational changes and a stronger emphasis on cost competitiveness allowed the company to improve gross profit and EBITDA despite lower sales. At the same time it kept investing in differentiation, with 174 new product registrations and 139 launches in 2025. That matters because ADAMA cannot beat active ingredient overcapacity through cost cutting alone. It also needs a better portfolio mix.

The Israeli mergers matter more than the accounting label suggests

First trigger: on December 31, 2025 the board approved non-material mergers between the company and ADAMA Makhteshim, ADAMA Agan and Agan Aroma and Fine Chemicals. On a consolidated basis that is classified as non-material, but operationally and financially it matters. The surviving company is expected to absorb the assets, liabilities and employees of the merged entities. The immediate report also states that loans drawn by Makhteshim and Agan under jointly granted facilities will transfer to the company, and related cross-guarantees and parent guarantees are expected to be cancelled.

The other side of that move is just as important. Completion still depends on Israeli Tax Authority approval, third-party and regulatory approvals and other closing conditions, and the agreements can be cancelled if the conditions are not met within 270 days. Beyond that, the company itself says it increased procurement and inventory partly to preserve business continuity during the merger of the Israeli entities. In other words, the simplification should help later, but in the short run it consumes working capital and management attention.

The bond buyback improved structure, but it also used real cash

Second trigger: in May 2025 ADAMA approved a buyback plan for up to $300 million of Series B bonds, and within days it repurchased NIS 642.4 million par value for about $268 million. That clearly improves the long-term debt structure and financing efficiency, but it is not free. The company recorded a $9.5 million financing loss on the buyback and, more importantly, used a meaningful amount of cash in the same year in which it was also trying to prove operating recovery.

The external environment improved only partially

Third trigger: channel inventory returned to pre-pandemic levels in most countries, which removes an important overhang from the last two years. But industry pricing is still under pressure because of active ingredient overcapacity, crop prices remain low and farmer profitability is still tight. The result is persistent just-in-time purchasing. That explains why margins can improve before sales recover.

Fourth trigger: as of the report publication date, even after regional tensions widened on February 28, 2026, the company's three manufacturing sites in Israel and the surrounding supply chain, including ports, were still operating without material delays. That is an important external confirming signal. It sharpens the point that the active bottleneck right now is not physical disruption in Israel, but pricing, customer credit and leverage quality.

Efficiency, Profitability and Competition

The core story of 2025 is that margins recovered before growth did. That sounds technical, but it is the whole point. If the improvement had arrived alongside rising prices, it would be easier to treat it as durable. Here it happened while prices still declined, which means the reader has to check exactly what drove the gain and what could fade again.

Sales still do not describe a clean recovery

Full-year sales declined 2% to $3.66 billion. Price reduced sales by roughly $90 million, volume added only about $11 million, and FX contributed another $3 million. So even after channel inventory normalized in parts of the market, ADAMA still did not return to a healthy pricing environment. In the fourth quarter, sales fell 5% to $962 million, with volume down 6% and price down 2%.

The regional picture explains why the year feels mixed. North America grew 10.9% to $934 million, and the report explicitly says a new launch was well received. Europe, Africa and the Middle East declined to $1.122 billion, but excluding Turkey volume actually increased. Latin America declined to $1.006 billion, even though Brazil benefited from higher volumes and new launches while the rest of LATAM saw weaker demand from channel partners focused on working capital. Asia Pacific fell 15.2% to $598 million, mainly because of India and weak weather conditions in Australia.

Profitability improved for real, but it was still an internal repair

Despite lower sales, adjusted gross profit rose 11% to $1.085 billion and adjusted gross margin increased to 29.7% from 26.2%. Adjusted EBITDA rose 25% to $486 million, with the margin moving to 13.3% from 10.4%. Management attributes that to two main drivers: better operational efficiency and lower costs of inventory sold.

That wording matters because it tells the reader both what improved and what still has not. Better operational efficiency is real if it holds. Lower-cost inventory sold is real too, but it is also more cyclical. If the pricing environment for active ingredients changes again, or if inventory has to be rebuilt on a different cost basis, part of that tailwind can weaken.

There is also a competitive point hiding underneath the numbers. ADAMA operates in an off-patent market, so it cannot build the story on exclusivity. Its real competitive edge comes from distribution quality, formulation capability, registration speed and the ability to bring a slightly better solution to the farmer without losing price competitiveness. That is why the data on 174 new registrations, 139 launches and 45% of agro sales coming from the differentiated portfolio is not just presentation garnish. It is the company's attempt to defend margin inside a market that still pressures price.

Positive adjusted profit is useful, but the gap to reported earnings is still large

This is the biggest yellow flag in the report. Reported EBITDA improved meaningfully to $431 million, but it still sits $55 million below adjusted EBITDA. At the bottom line, the gap is even sharper: the reported net loss of $140.4 million only becomes adjusted net income of $5 million after $145.4 million of adjustments.

Some of those adjustments are clearly one-off or non-cash. But not all of them disappear tomorrow morning. Amortization of transfer assets from the ChemChina-Syngenta transaction contributed $21.9 million of adjustments in 2025, and the company explicitly says these charges will continue until 2032 and remain meaningful until 2028. Restructuring and advisory costs of $47.6 million, and fixed asset and inventory impairments of $53.2 million, are also not random noise. They are part of the price of moving to a leaner operating model.

So the positive adjusted profit does tell the reader that the direction is better. It does not yet prove that the gap between ongoing economics and reported accounting has become small.

Cash Flow, Debt and Capital Structure

The key insight here is that ADAMA's 2025 can be described through two different cash lenses, and both are correct. The problem starts when the reader looks at only one of them.

The business generated more cash

If the lens is recurring cash generation, 2025 was clearly better. Operating cash flow increased to $350 million from $313 million, and free cash flow rose to $231 million from $157 million. The company ties that to better collections and stronger business earnings, even though part of the benefit was offset by higher procurement payments.

That is a legitimate normalized cash-generation read, and it is positive. It says the business is producing more cash before capital-structure decisions.

The all-in cash picture is tighter

But the all-in cash flexibility picture is less clean. Cash and short-term investments declined to $446 million from $470 million despite the better operating cash flow. The reason is straightforward: in 2025 ADAMA also spent about $268.8 million on the bond buyback, repaid $68.3 million of bond principal, repaid $127 million of long-term loans and other liabilities, and paid about $25.5 million of lease principal.

So anyone who stops at the sentence "cash flow improved" misses the financing layer. ADAMA is indeed generating more cash, but a good part of that cash is already being absorbed by capital-structure moves. That is not necessarily negative. For a bond-only listed company it is even rational. But it does mean true flexibility is still narrower than adjusted EBITDA alone might suggest.

Working capital improved through collections and payables, not through lighter inventory

Trade working capital fell to $1.747 billion from $1.877 billion. That looks good, and it supported cash flow. But once the reader opens the numbers, inventory actually increased to $1.569 billion from $1.458 billion. The reduction in working capital came mainly from lower receivables, down from $1.130 billion to $1.045 billion, and from longer payable terms. Customer credit days fell slightly to 129 from 131, inventory days were essentially unchanged at 216 versus 215, and supplier credit days rose to 136 from 130.

That point defines the quality of the improvement. If inventory had fallen materially, the reader could say the business became structurally lighter. That is not what happened. ADAMA procured more to capture the market recovery and to secure business continuity during the merger of the Israeli entities. That may be a rational choice, but it still leaves the balance sheet heavy.

One more small but important detail: trade payables still include $148 million of supplier finance arrangements, down from $222 million a year earlier. So the company did not manufacture all of the improvement through supplier finance, but it is still relying on operating funding structures as part of the cash picture.

Leverage is far from covenant pressure, but heavier than the headline ratio suggests

Total debt declined to $2.118 billion from $2.218 billion. That includes $766 million of bonds, $490 million of short-term related-party loans, $336 million of long-term related-party loans, $325 million of short-term bank debt and commercial paper, and $202 million of long-term bank loans. The company also has $530 million of unused committed credit lines from banks and another $260 million from related parties.

At the covenant level the picture is comfortable. Net debt to equity stands at 0.5 against a 1.25 ceiling. Net debt to EBITDA stands at 1.9 against a ceiling of 4. Equity is $1.656 billion against a $1.22 billion floor. On the formal rules, there is no immediate pressure.

But the problem is not covenant headroom. It is the difference between covenant leverage and economic leverage. The board report shows net debt of $1.639 billion. The presentation shows the 1.9x ratio based on covenant net debt of only $813 million and explicitly notes that the covenant definition excludes securitization and SG loans. That means the easiest ratio to quote is also the least representative of the full funding stack.

This is not a call that the debt is dangerous tomorrow morning. On the contrary, covenant headroom is wide. It is a call to read ADAMA through the full debt picture, especially because the current ratio fell to 1.13 from 1.45 and the quick ratio fell to 0.63 from 0.85. The balance sheet improved, but it is not yet light.

Outlook

There are four points that should frame 2026 before getting into detail:

• First finding: a meaningful part of the 2025 margin recovery came from efficiency and lower-cost inventory sold, so 2026 has to prove those margins can hold without the same tailwind.
• Second finding: capacity is not the active bottleneck. Average plant utilization is around 65% to 70%, so if volume recovers there is room for operating leverage without heavy near-term expansion spending.
• Third finding: North America and the differentiated portfolio are currently the cleanest growth proof points. APAC and Turkey remain the obvious drag buckets.
• Fourth finding: anyone following only the 1.9x ratio will miss the real 2026 test. The next reports have to be judged through full net debt, receivables quality and inventory discipline as well.

2026 is a proof year, not a breakout year

Management is aiming for renewed top-line growth while preserving business quality and the discipline of Fight Forward. It is also emphasizing stronger commercial capabilities, ongoing investment in the differentiated portfolio and innovation pipeline, and continued manufacturing optimization, including the merger of the Israeli entities. That is a clear strategic line. The problem is that the market ADAMA operates in is still not offering clean support.

That is why 2026 looks like a proof year. For the thesis to strengthen, the company has to show revenue growth without giving up gross margin again, keep EBITDA strong even as the inventory-cost tailwind normalizes, and turn the working-capital improvement into something that does not rely mainly on collections and payables.

Where positive surprise can come from

There are several possible sources of upside surprise. The first is North America, which already delivered double-digit growth in 2025. The second is the differentiated portfolio and the new launches, which can help margin even if broader industry pricing remains weak. The third is the manufacturing base. With average utilization below full capacity and management still optimizing the network, a recovery in volume does not necessarily require heavy immediate investment.

Where the thesis can break

There are also clear failure points. Another leg down in active ingredient pricing, renewed weakness in APAC, or fresh credit stress among LATAM distributors can turn 2025 into a good cost-saving year inside a weak industry rather than the start of a new phase. The Israeli mergers can also delay part of the expected benefit if execution drags or if they continue to consume too much working capital and management attention.

Risks

The risks here do not sit only in the debt line. They are spread across the industry cycle, working capital, regulation and the relationship with the parent group.

Industry pricing is still not in a comfortable place

Active ingredient overcapacity, low crop prices and weak farmer profitability keep the industry in an environment where pricing power is hard to regain. ADAMA proved in 2025 that it can earn more even in those conditions, but if price pressure deepens the company will again need to find internal savings to defend margin.

Distributor credit remains a critical checkpoint

The company already says that higher adjusted operating expenses in 2025 were partly driven by credit-loss provisions due to liquidity issues at certain LATAM distributors. Trade receivables still stand at $1.045 billion, and estimated credit-loss expense in 2025 was about $16 million, mainly because of Brazil. There are protective layers here, including credit insurance renewed through October 1, 2027 with annual cumulative coverage of $150 million and indemnification of up to 90% of the debt, and securitization programs. But the very need for those tools says the risk has not disappeared. It is being managed.

Economic leverage is heavier than the formal covenant view

The company is compliant with a wide margin, but about $467 million of bank financing includes cross-default clauses. If performance weakens materially, the market will quickly focus on total debt, the quick ratio and access to credit lines rather than only the 1.9x ratio. The risk here is not immediate breach. It is a sharp change in interpretation if one of the improvement engines, margin, receivables or inventory, reverses.

Environmental regulation and litigation are not background noise

ADAMA is a global chemical manufacturer, so environmental costs are not a cosmetic line item. The company expects environmental costs of about $189 million across 2026 to 2028. At the same time it is managing soil remediation activity at the Be'er Sheva plant and a range of claims, including patent and product liability matters. For now management says there is no material effect beyond what has already been provided or insured. It is still an area that can absorb cash and management focus.

The parent-group relationship is both support and dependency

Related-party loans reached $825.8 million at the end of 2025, and interest expense to related parties was $38.6 million. That gives ADAMA financing support and additional credit capacity. It also leaves the local story dependent on the willingness and ability of the wider group to keep supporting that structure. Anyone treating those intra-group loans as if they were the same as permanent external capital is smoothing over an important distinction.

Conclusions

ADAMA exits 2025 stronger operationally, but still not economically clean. Efficiency improved, margins rose, operating cash flow strengthened and covenant headroom is wide. On the other hand, pricing power has not returned, a meaningful part of the working-capital improvement came from collections and payable terms, and economic leverage is heavier than the headline ratio suggests.

In the short-to-medium term, what changes the market interpretation is not another Fight Forward slide. It is a combination of three things in the next reports: revenue returning to growth, margins holding up while that happens, and continued reduction in full net debt. If that combination appears, 2025 will look like the start of a move to a better-quality business. If it does not, 2025 will look more like a good repair year inside an industry that is still not settled.

Current thesis: ADAMA improved its operating economics in 2025, but it still has not proved that the improvement can stand without help from lower inventory costs and working-capital execution.

What changed: relative to 2024, the story is no longer one of survival and balance-sheet defense. It is now an attempt to turn internal repair into durable business improvement.

Counter-thesis: it is possible that the hardest part is already behind the company, channel inventory has normalized, the operating model is leaner, North America and differentiated products can bring growth back, and 2025 was only the first step in a multi-year normalization.

What could change the market read in the near term: renewed growth without margin giveback, visible progress in the Israeli mergers, and continued decline in economic net debt rather than only covenant leverage.

Why this matters: if ADAMA can turn internal efficiency into durable improvement in revenue quality, collections and leverage, the quality of the business changes. If not, the 2025 improvement remains mostly internal and still vulnerable to the industry cycle.

Across the next 2 to 4 quarters, ADAMA needs to prove three simple and difficult things: sales have to start growing again, inventory and receivables cannot run away again, and the gap between covenant debt and economic debt has to keep narrowing. If one of those breaks, the thesis weakens quickly. If all three hold, 2025 will be remembered as a genuine inflection point rather than only a successful repair year.